SC 13G/A: NEKTAR THERAPEUTICS
Ticker: NKTR · Form: SC 13G/A · Filed: Nov 14, 2024 · CIK: 906709
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by NEKTAR THERAPEUTICS.
Risk Assessment
Risk Level: low
Filing Stats: 1,406 words · 6 min read · ~5 pages · Grade level 10.2 · Accepted 2024-11-14 09:18:10
Key Financial Figures
- $0.0001 — me of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 6402
Filing Documents
- deeptrack-nktr093024a2.htm (SC 13G/A) — 99KB
- 0001172661-24-004734.txt ( ) — 101KB
(a)Name of Issuer
Item 1. (a)Name of Issuer NEKTAR THERAPEUTICS
(b)Address of Issuer’s Principal
Item 1. (b)Address of Issuer’s Principal Executive Offices 455 Mission Bay Boulevard South San Francisco, CA 94158
(a)Names of Persons Filing
Item 2. (a)Names of Persons Filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
( b)Address
Item 2. ( b)Address of Principal Business Office: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c) Citizenship
Item 2. (c) Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)Title of Class of Securities
Item 2. (d)Title of Class of Securities Common Stock, par value $0.0001 (the “Common Stock”)
(e) CUSIP No
Item 2. (e) CUSIP No.: 640268108 CUSIP No. 640268108 SCHEDULE 13G/A Page 6 of 9 Pages
If
Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: CUSIP No. 640268108 SCHEDULE 13G/A Page 7 of 9 Pages Item 4.Ownership Information with respect to the Reporting Persons' ownership of the Common Stock as of September 30, 2024, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 184,079,479 Common Stock outstanding as of August 2, 2024, according to the issuer’s Form 10-Q, filed with the SEC on August 9, 2024. Item 5.Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial